Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Will Highlight Celebrex Safety In ’07

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm to address cardiovascular safety for the COX-2 inhibitor in a new DTC advertising campaign.

You may also be interested in...



Celebrex Ad Prompts Criticism From Consumer Group

Public Citizen urges FDA to order Pfizer to stop “dangerous” and “misleading” direct-to-consumer ad.

Celebrex Ad Prompts Criticism From Consumer Group

Public Citizen urges FDA to order Pfizer to stop “dangerous” and “misleading” direct-to-consumer ad.

Validity of Celebrex Patents Upheld In Court, Barring Generics Until 2015

ANDA filer Teva says it will appeal a federal court decision over the COX-2 inhibitor.

Related Content

Topics

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel